Search

Close
Research
Home > Research > Faculty
Research

DU Yuzhen  

  • Doctoral Supervisor, Chief Technician
  • Department: Laboratory Medicine
  • Research Area: Clinical Molecular Diagnostic
  • Research Interests: Mechanism of bone metastasis in lung cancer; early diagnosis and monitoring models for bone metastasis in lung/breast cancer.
  • Contact: yzdu@sjtu.edu.cn
Biography Positions Publications Research Projects Patents
  • PhD, Molecular Toxicology, Suzhou Medical College (Department of Preventive Medicine), 2005
  • MSc, Molecular Toxicology, Suzhou Medical College (Department of Preventive Medicine), 2002
  • BSc, Laboratory Medicine, West China Center of Medical Sciences of Sichuan University (School of Public Health), 1994
  • Administrative Deputy Director, Department of Laboratory Medicine (Clinical Laboratory), Shanghai Sixth People's Hospital
  1. Representative Publications (recent years):
  2. Xingyu Liu#, Rong Qiu#, Pengcheng Gui, Lirong Wei, Yue Lu, Yan Deng, Yang Xue, Yingyang Su, Qin Huang, Yuzhen Du*, Osteoclast-Derived Arachidonic Acid Triggers Dormant Lung Adenocarcinoma Cell Activation, iScience. 2025, 28(5)112167. IF=4.6, Q1
  3. Rong Qiu#, Yan Deng#, Yue Lu, Xingyu Liu, Qin Huang, Yuzhen Du*. ITGB3-enriched extracellular vesicles mediate the formation of osteoclastic pre-metastatic niche to promote lung adenocarcinoma bone metastasis. Mol Carcinog. 2024,63(11):2190-2204
  4. Xiaoyan Teng, Kun Han, Wei Jin, Liru Ma, Lirong Wei, Daliu Min, Libo Chen**, Yuzhen Du*. Development and Validation of an Early Diagnosis Model for Bone Metastasis in Non-Small Cell Lung Cancer Based on Serological Characteristics of the Bone Metastasis Mechanism. eClinical Medicine. 2024, 72,102617. IF=9.6, Q1. 
  5. Teng X#, Hu L#, Shen J, Hu J, Wu X*, Du Y*. Plasma SARS-CoV-2 N antigen is a powerful molecular marker for early detection of severe COVID-19 in patients and monitoring disease progression. Clin Chim Acta. 2023; 551,117586. IF=5.0, Q1. 
  6. Xiaoyan Teng#, Yu Wang#, Liuxia You#, Lirong Wei, Chao Zhang**, Yuzhen Du*. Screening a DNA Aptamer Specifically Targeting Integrin β3 and Partially Inhibiting Tumor Cell Migration. Anal Chem. 2023 Aug 22;95(33):12406-12418. IF=7.4, Q1.
  7. Chao D, Xu X, Miao Y, Yang L, Gao Q, Xu R, Tian Y, Zhao Y, Du Y*, Han D*. Covalent stabilization of DNA nanostructures on cell membranes for efficient surface receptor-mediated labeling and function regulations. Sci China Chem, 2022, 65(11): 2327-2334.
  8. Wu Z, Yang C, Shen Y, Zhang Q, Tang X, Wang D, Xu Y, Cao G, Song X, Ma Y, Fan H, Lu H, Li Y, Li X, Shen Y, Zhang C, Zhu M, Teng X, Du Y*, Guan M*.. Time series analysis revealed prognostic value of continuous nasopharyngeal SARS-CoV-2 nucleic acid quantification for COVID-19: A retrospective study of >3000 COVID-19 patients from 2 centers. Clin Chim Acta. 2023 Feb 1;540:117227.
  9. Xiaoyan Teng, Lirong Wei, Liming Han, Daliu Min, Yuzhen Du*. Establishment of serological molecular model for early diagnosis and progress monitoring of bone metastasis in lung cancer. BMC Cancer. 2020; 20(1): 562
  10. Shaofei Cheng, Fengying Qian, Qin Huang, Lirong Wei, Yawen Fu ,Yuzhen Du*. HOXA4, down-regulated in lung cancer, inhibits the growth, motility and invasion of lung cancer cells. Cell Death & Disease.  2018.9(5): 465. doi:10.1038/s 41419-018-0497-x
  11. Qianlin Xia, Rong Qiu, Yue Lu, Qiong Zhang, Yuzhen Du*. Construction and clinical significance of prognostic risk model related to m6A methylation regulators in lung adenocarcinoma. Practical Oncology Journal, 2023, 37(1): 39-45.
  • 07/01/2025 – 06/30/2028: 
    Industry–academia collaboration / IIT (KJ-2025-365; ChiCTR2500102282), ¥2,000,000. Intelligent early-warning system for bone metastasis based on serum bone turnover markers across pan-cancer patients. Project Leader.
  • 12/01/2024 – 11/30/2027: 
    Pudong New Area Health Commission Joint Research Program (PW2024D-17), ¥200,000. Development and application of an early diagnosis model for breast cancer bone metastasis based on serum molecular features. Project Leader.
  • 01/01/2020 – 12/31/2023: 
    National Natural Science Foundation of China (81974315). Role and diagnostic value of osteotropism-related exosomal miR‑22 in pre-metastatic niche formation of lung cancer bone metastasis. Project Leader. (Completed)
  • 12/01/2020 – 11/30/2023: 
    Shanghai Science & Technology Commission, Medical Innovation Research Program (20Y11903300), ¥300,000. Validation and development of a serum molecular model for early diagnosis of tumor bone metastasis.  Project Leader.(Completed)
  • 09/01/2019 – 11/30/2022:
    Pudong Science & Technology Commission Innovation Project (PKJ2019-Y05). Clinical value of pleural/ascites ctDNA in targeted cancer therapy. Project Leader. (Completed)
  • 10/01/2016 – 09/30/2019
    Shanghai Science & Technology Commission(16DZ1930208). SMA Family Linkage Inheritance Analysis Study. Project Leader. (Completed)
  1. [Yuzhen Du, Xiaoyan Teng] (2026), “Tumor Bone Metastasis Prediction System and Method Based on Bone Metastasis-Specific Bone Markers”, ZL 2023 1 1174107.3, China National Intellectual Property Administration.
  2. [Yuzhen Du, Rong Qiu, Xingyu Liu] (2025), “Biomarker for Assisting in Diagnosis of Lung Adenocarcinoma Bone Metastasis”, ZL 202510018013.X, China National Intellectual Property Administration.
  3. [Yuzhen Du, Rong Qiu] (2025), “Biomarker for Assessing Risk of Disease Progression in Lung Adenocarcinoma Bone Metastasis and Use Thereof”, Application No. 2025115231670, China National Intellectual Property Administration.
  4. [Yuzhen Du, Rong Qiu, Yue Lu] (2023), “A Human High Bone Metastasis Lung Adenocarcinoma Cell Line and Its Construction Method and Application”, Application No. 202311464185.7, China National Intellectual Property Administration.
     

Copyright © 2024, All Rights Reserved.